

A&I

ANÄSTHESIOLOGIE & INTENSIVMEDIZIN

Offizielles Organ: Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e. V. (DGAI)
Berufsverband Deutscher Anästhesistinnen und Anästhesisten e. V. (BDA)

Organ: Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e. V. (DIVI)



Pseudocholinesterase Deficiency

orphan**anesthesia**

a project of the German Society
of Anaesthesiology and Intensive Care Medicine

SUPPLEMENT NR. 10 | 2025

OrphanAnesthesia –

ein krankheitsübergreifendes Projekt des Wissenschaftlichen Arbeitskreises Kinderanästhesie der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e.V.

Ziel des Projektes ist die Veröffentlichung von Handlungsempfehlungen zur anästhesiologischen Betreuung von Patientinnen und Patienten mit seltenen Erkrankungen. Damit will OrphanAnesthesia einen wichtigen Beitrag zur Erhöhung der Patientensicherheit leisten.

Patientinnen und Patienten mit seltenen Erkrankungen benötigen für verschiedene diagnostische oder therapeutische Prozeduren eine anästhesiologische Betreuung, die mit einem erhöhten Risiko für anästhesieassoziierte Komplikationen einhergehen. Weil diese Erkrankungen selten auftreten, können Anästhesistinnen und Anästhesisten damit keine Erfahrungen gesammelt haben, sodass für die Planung der Narkose die Einholung weiterer Information unerlässlich ist. Durch vorhandene spezifische Informationen kann die Inzidenz von mit der Narkose assoziierten Komplikationen gesenkt werden. Zur Verfügung stehendes Wissen schafft Sicherheit im Prozess der Patientenversorgung.

Die Handlungsempfehlungen von OrphanAnesthesia sind standardisiert und durchlaufen nach ihrer Erstellung einen Peer-Review-Prozess, an dem eine Anästhesistin bzw. ein Anästhesist sowie eine weitere Krankheitsexpertin bzw. ein weiterer Krankheitsexperte (z. B. Pädiaterin bzw. Pädiater oder Neurologin bzw. Neurologe) beteiligt sind. Das Projekt ist international ausgerichtet, sodass die Handlungsempfehlungen grundsätzlich in englischer Sprache veröffentlicht werden.

Ab Heft 5/2014 werden im monatlichen Rhythmus je zwei Handlungsempfehlungen als Supplement der A&I unter www.ai-online.info veröffentlicht. Als Bestandteil der A&I sind die Handlungsempfehlungen damit auch zitierfähig. Sonderdrucke können gegen Entgelt bestellt werden.

OrphanAnesthesia –

a project of the Scientific Working Group of Paediatric Anaesthesia of the German Society of Anaesthesiology and Intensive Care Medicine

The target of OrphanAnesthesia is the publication of anaesthesia recommendations for patients suffering from rare diseases in order to improve patients' safety. When it comes to the management of patients with rare diseases, there are only sparse evidence-based facts and even far less knowledge in the anaesthetic outcome. OrphanAnesthesia would like to merge this knowledge based on scientific publications and proven experience of specialists making it available for physicians worldwide free of charge.

All OrphanAnesthesia recommendations are standardized and need to pass a peer review process. They are being reviewed by at least one anaesthesiologist and another disease expert (e.g. paediatrician or neurologist) involved in the treatment of this group of patients.

The project OrphanAnesthesia is internationally oriented. Thus all recommendations will be published in English.

Starting with issue 5/2014, we'll publish the OrphanAnesthesia recommendations as a monthly supplement of A&I (Anästhesiologie & Intensivmedizin). Thus they can be accessed and downloaded via www.ai-online.info. As being part of the journal, the recommendations will be quotable. Reprints can be ordered for payment.

Bisher in A&I publizierte Handlungsempfehlungen finden Sie unter:

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu

Find a survey of the recommendations published until now on:

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu

Projektleitung

Dr. med. Christine Gaik, DESAIC, FESAIC

Oberärztin
Klinik für Anästhesie und Intensivtherapie
Universitätsklinikum Gießen und Marburg GmbH,
Standort Marburg
Baldingerstraße
35033 Marburg, Deutschland
E-Mail:
gaikc@med.uni-marburg.de

Priv.-Doz. Dr. med. Philipp Gude, MHBA

Geschäftsführender Oberarzt
Klinik für Anästhesiologie und Intensivmedizin
Universitätsklinikum
St. Elisabeth-Hospital
Bleichstraße 15
44787 Bochum, Deutschland
E-Mail:
philipp.gude@ruhr-uni-bochum.de

orphananesthesia

Anaesthesia recommendations for Pseudocholinesterase Deficiency

Disease name: Pseudocholinesterase deficiency

ICD 10: E88.0 (ICD 11: 5C59.Y)

Synonyms: Butyrylcholinesterase deficiency, Synonyms of pseudocholinesterase: butyrylcholinesterase, serum cholinesterase, plasma cholinesterase, false cholinesterase

Disease summary:

Pseudocholinesterase deficiency is characterized by insufficiently low levels of pseudocholinesterase. Pseudocholinesterase is a plasma enzyme that metabolizes choline esters, such as the muscle relaxants succinylcholine and mivacurium [1]. The aetiology of pseudocholinesterase deficiency can be genetic (hereditary) or acquired. Patients typically present with prolonged post-operative apnoea and paralysis following administration of either succinylcholine or mivacurium during the induction of general anaesthesia.

Hereditary pseudocholinesterase deficiency (ICD-10 E88.0) is an autosomal recessive condition caused by atypical variants of the butyrylcholinesterase (BChE) gene located on chromosome 3 (3q26.1-q26.2). The prevalence of homozygosity is estimated at 1:3,000, while heterozygosity has an estimated prevalence of 1:25 [2, 3]. Interestingly, the prevalence of pseudocholinesterase deficiency seems to be much higher in certain ethnic groups, such as individuals of Turkish or Egyptian descent [1, 4], the Vysya community in India [5], or a number of Alaskan Native communities [6].

Heterozygosity may also be associated with a slightly prolonged duration of action of succinylcholine and mivacurium.

Acquired forms of the condition may be caused by pregnancy, liver disease, and malnutrition, amongst others [2]. Furthermore, other potential causes of reduced pseudocholinesterase levels include malignancy [7], renal disease [8], and burns [9]. Additionally, a number of drugs may inhibit pseudocholinesterase activity [e.g., 10].

Acquired causes of the deficiency seldom result in clinically noticeable symptoms. This is because enzyme activity does not usually fall below 50%, i.e. the estimated threshold of clinical relevance [11]. Nevertheless, a combination of genetic and acquired causes (such as pregnancy and heterozygosity) could cumulatively result in a clinically relevant reduction of enzyme activity, thus causing clinical symptoms [2, 11, 12].

A routine preoperative work-up will not usually identify pseudocholinesterase deficiency unless a patient's medical or family history is remarkable in this regard. Diagnoses are typically made once a patient fails to adequately recover from paralysis following an administration of succinylcholine or mivacurium. Laboratory tests such as enzyme activity assays and the so-called dibucaine test confirm the diagnosis. A genetic analysis of the patient (and their relatives) can help establish the aetiology of the condition.

► **Citation:** Schulze-Berge J, Hüppe T: Pseudocholinesterase Deficiency. Anästh Intensivmed 2025;66:S144–S152. DOI: 10.19224/ai2025.S144

Pseudocholinesterase deficiency has an excellent prognosis. However, a causal treatment does not currently exist. Instead, treatment is typically supportive, consisting of prolonged mechanical ventilation, sedation, and monitoring of neuromuscular function until the patient can be safely extubated.

Medicine is in progress



Perhaps new knowledge

Every patient is unique

Perhaps the diagnosis is wrong



Find more information on the disease, its centres of reference and patient organisations on Orphanet: www.orpha.net

Emergency information

A	AIRWAY / ANAESTHETIC TECHNIQUE	Both general and regional anaesthesia may be used. Careful selection of muscle relaxant for induction. Neuromuscular monitoring is essential to assess recovery.
B	BLOOD PRODUCTS (COAGULATION)	No particularities.
C	CIRCULATION	No particularities.
D	DRUGS	Contraindication for two muscle relaxants: succinylcholine and mivacurium. Ester local anaesthetics have a prolonged duration of effect as well as a greater risk of side effects.
E	EQUIPMENT	Prolonged post-operative ventilation and monitoring required for persistent paralysis and apnoea in symptomatic patients.

Typical surgery

Pseudocholinesterase deficiency may present as a complication of general anaesthesia for any surgical procedure requiring administration of a muscle relaxant (typically for induction). However, the condition itself is not associated with problems that would typically require surgical correction. As a result, there are no "typical surgeries" that these patients would predominantly present for.

Type of anaesthesia

Both general and regional anaesthesia are principally safe and feasible in patients with pseudocholinesterase deficiency. However, careful selection of an appropriate muscle relaxant is crucial. Succinylcholine and mivacurium should not be used in patients with known or suspected pseudocholinesterase deficiency.

Necessary additional pre-operative testing (beside standard care)

A routine pre-operative work-up will not usually flag pseudocholinesterase deficiency in patients without anamnestic particularities. However, if pseudocholinesterase deficiency is

suspected pre-operatively because of a remarkable medical or family history, laboratory tests such as measurement of pseudocholinesterase plasma activity can help confirm the diagnosis. Another commonly used test is the dibucaine test (functional test). It provides the so-called dibucaine number, which indicates the percent of pseudocholinesterase activity that is inhibited by the local anaesthetic dibucaine under standard testing conditions (normal range > 70%) [2]. Heterozygotes typically have a dibucaine number between 40 and 70%, while homozygotes typically fall below 20% [13, 14].

If a suspected clinical diagnosis can be confirmed by laboratory tests, genetic testing using polymerase chain reaction (PCR) can help determine a hereditary aetiology of the disease [1, 2].

If the diagnosis is suspected anamnestically, but pre-operative tests are not available or feasible (e.g., urgent or emergency surgeries), mivacurium and succinylcholine should be avoided. In these cases, alternatives, such as rocuronium (also in combination with sugammadex) or atracurium, should be used instead. Patients should be informed about the suspected deficiency and encouraged to undergo testing for the disease.

Particular preparation for airway management

Succinylcholine and mivacurium should not be used for muscle relaxation. If patients require a rapid sequence induction (RSI), rocuronium should be used instead of succinylcholine (rocuronium RSI dose: 0.9 – 1.2mg/kg). Similarly, rocuronium can also be used for short procedures for which mivacurium or succinylcholine might otherwise be used. Despite its significantly longer duration of effect, rocuronium is an attractive alternative to the other two muscle relaxants because it can be antagonised safely by using sugammadex.

In terms of equipment, the airway management of a patient with pseudocholinesterase deficiency does not require any particular preparation.

Particular preparation for transfusion or administration of blood products

None required. According to the literature, pseudocholinesterase deficiency can be treated using transfusions of whole blood [15], fresh frozen plasma [16] or serum human pseudocholinesterase [17, 18] to increase enzyme activity and shorten recovery time. However, given the excellent prognosis under conservative treatment (i.e., continued mechanical ventilation and sedation) the additional risks and costs of a transfusion are generally deemed unnecessary [2].

Particular preparation for anticoagulation

None required.

Particular precautions for positioning, transportation and mobilisation

None required.

Interactions of chronic disease and anaesthesia medications

The reduction of enzyme activity causes changes in the metabolism of all choline esters that are usually hydrolysed by pseudocholinesterase. This affects the metabolism of two muscle relaxants, succinylcholine and mivacurium, which have to be broken down via alternate pathways instead. Furthermore, only approximately 40% of patients, who were later referred for suspected pseudocholinesterase deficiency, underwent neuromuscular monitoring [21].

Anaesthetic procedure

Both general and regional anaesthesia are principally feasible and should be used as indicated. Furthermore, general anaesthesia can be administered as TIVA or with volatile anaesthetics. However, as outlined above, the choice of an appropriate muscle relaxant is crucial because the use of mivacurium or succinylcholine is contraindicated in patients with pseudocholinesterase deficiency.

Particular or additional monitoring

Neuromuscular monitoring (e.g., train-of-four testing (TOF)) is essential, especially in patients with delayed emergence from anaesthesia. It is a quick, easy, and inexpensive way of identifying pseudocholinesterase deficiency, or to exclude it as a differential diagnosis. Given the almost ubiquitous availability of neuromuscular monitoring, it is advisable to evaluate patients' neuromuscular status every time general anaesthesia has been induced with a muscle relaxant – but especially whenever mivacurium or succinylcholine have been administered. This is certainly not a new recommendation [e.g., 19, 20]. However, registry data from the Danish Cholinesterase Research Unit have shown that 72% of patients with pseudocholinesterase deficiency experienced premature awakening, defined as discontinuation of anaesthesia despite (unrecognised) residual paralysis [21]. Furthermore, only approximately 40% of patients who were later referred for suspected pseudocholinesterase deficiency had undergone neuromuscular monitoring [21]. Moreover, among those who were monitored, only 20% of patients underwent monitoring at the end of the surgical procedure before discontinuation of anaesthesia. The vast majority of patients (80%) were monitored immediately after induction, when neuromuscular monitoring cannot help identify those suffering from prolonged paralysis. Thus, there appears to be a gap between what is considered to be “fundamental” clinical knowledge and observable clinical practice [20-22]. Importantly, this practice might result in relevant medicolegal issues and should therefore be avoided.

Furthermore, if used, TIVA should always be used in conjunction with a processed EEG to monitor the depth of anaesthesia. Patients with pseudocholinesterase deficiency have been shown to have an increased risk of awareness during emergence [23]. Those who consciously experience paralysis at the end of a procedure also have an increased risk of developing post-traumatic stress disorder (PTSD) in the long run [23]. A combination of light sedation and residual paralysis is characteristic of this condition and can easily be diagnosed using relatively inexpensive and widely available standard monitoring, such as neuromuscular monitoring and a processed EEG.

Possible complications

Delayed emergence with prolonged residual paralysis resulting in post-operative apnoea is the most important complication of pseudocholinesterase deficiency [e.g., 1, 2, 18, 21, 24, 25]. Furthermore, post-anaesthetic paralysis and apnoea are associated with a number of risks and sequelae.

First, as outlined above, patients have an increased risk of premature awakening and awareness during emergence, and may therefore consciously experience paralysis [23]. This is associated with intense distress, and puts patients at an increased risk of developing PTSD [23]. Substandard care (no routine use of neuromuscular monitoring when succinylcholine or mivacurium are used) might result in medicolegal and financial risks for the anaesthetist.

Second, if apnoea is not recognised or interpreted correctly, extubation may be performed prematurely. This is associated with an increased risk of respiratory complications, such as oxygen desaturation, aspiration, and a need for reintubation [21].

Third, if the cause of delayed emergence is not correctly identified, patients may be exposed to unnecessary medication administered to treat differential diagnoses of delayed emergence (e.g., opioid overhang: naloxone; central anticholinergic syndrome: physostigmine; benzodiazepine overhang: flumazenil [21]). Most importantly, if apnoea and delayed emergence are incorrectly attributed to opioid overhang, administration of naloxone may increase distress by removing sufficient analgesia in a prematurely awakened, aware, and paralysed patient [21].

Finally, patients may face risks outside of the immediate perioperative setting, even though most will be asymptomatic in their daily lives [26]: Patients with pseudocholinesterase deficiency may face an increased risk of potentially fatal side effects of cocaine, which is also metabolised by pseudocholinesterase [27]. Additionally, pseudocholinesterase deficiency has recently been suggested as a potential risk factor for sudden infant death syndrome [28]. However, this suggestion is based on limited data and requires further investigation.

Post-operative care

No special precautions are required in patients with diagnosed pseudocholinesterase deficiency in whom succinylcholine or mivacurium were not used. However, if patients received either of these muscle relaxants – either because the condition was previously undiagnosed or not communicated – post-operative mechanical ventilatory support and monitoring on an intensive care unit (ICU) must be provided.

Following the initial presentation, patients and their family need to be counselled on the details and consequences of their condition and the option of genetic testing. They also need to be issued a medical alert card detailing their condition for future interventions under general anaesthesia.

Disease-related acute problems and effect on anaesthesia and recovery

The condition affects the metabolism of drugs commonly used to induce anaesthesia. Specifically, it affects the muscle relaxants succinylcholine and mivacurium, causing prolonged paralysis and apnoea following administration, as outlined above. Post-anaesthetic recovery may be significantly prolonged and patients may require hours of supportive treatment before they can be safely extubated.

Furthermore, the metabolism of ester local anaesthetics (tetracaine, cocaine and procaine) is also affected, possibly resulting in a prolonged duration of effect as well as a greater risk of side effects [1]. However, amides are more commonly used in clinical practice than esters [29] and are safe to use in patients with pseudocholinesterase deficiency (e.g., [30]).

Psychologically, patients are exposed to an increased risk of experiencing acute and chronic stress following the operation. If sustained paralysis is not duly noted, they may wake up and consciously experience paralysis, thus putting them at an increased risk of developing PTSD [23].

Ambulatory anaesthesia

Ambulatory anaesthesia is not contraindicated in patients with pseudocholinesterase deficiency. The recommendations for general and local anaesthesia outlined above also apply in the ambulatory setting.

Obstetrical anaesthesia

The recommendations for general anaesthesia outlined above also apply to obstetrical anaesthesia. However, given the different mechanisms that may lead to clinical symptoms, pregnant patients represent an important and interesting patient subgroup. As mentioned above, the simultaneous presence of several acquired and/or genetic causes of pseudocholinesterase deficiency makes a clinically noticeable, cumulative reduction in enzyme activity more likely [11]. A simultaneous presence of multiple causes of pseudocholinesterase deficiency is more likely in pregnant women, because pregnancy itself influences pseudocholinesterase levels: During pregnancy, pseudocholinesterase activity decreases by approximately 20% from the first trimester, and falls by another 33% in the first days after delivery, before reaching pre-pregnancy levels approximately 6 weeks postpartum [1, 2, 11, 12, 31, 32]. The reasons for this reduction are not yet well understood. It has been suggested that a combination of factors might contribute, including haemodilution, impaired hepatic function, albumin loss, malnutrition, and effects of oestrogen [32-35]. Among patients with HELLP syndrome, significantly reduced levels of pseudocholinesterase activity seem to be more common, possibly because of patients' impaired liver function [36].

Finally, one unique aspect of obstetrical anaesthesia is that it involves caring for two patients. It has been reported that pseudocholinesterase deficiency can present in neonates delivered by caesarean section following induction of general anaesthesia with succinylcholine, causing "post-operative" apnoea and paralysis in homozygous infants immediately after birth [11, 37]. Furthermore, a standard dose of succinylcholine administered to a homozygous mother during induction of anaesthesia may create a sufficiently large concentration gradient in the placenta to allow succinylcholine to reach the neonate's circulation, causing temporary muscle weakness independently of the child's own genetic status as a hetero- or homozygote [38].

It has been argued that the placenta provides a relative rather than absolute barrier for molecules with low lipid solubility and a high degree of ionization, such as muscle relaxants [11, 37-39]. Consequently, a transfer of pharmacologically active amounts of these substances might occur in homozygous mothers with hereditary pseudocholinesterase deficiency. They cannot hydrolyse succinylcholine as quickly or efficiently as healthy controls and are therefore exposed to a relative overdose in various tissues, such as the placenta [11].

As such, hereditary pseudocholinesterase deficiency may represent an incredibly rare differential diagnosis of neonatal apnoea, which should primarily be considered if succinylcholine (or mivacurium) was administered to the mother, especially if she is also presenting with prolonged post-anaesthetic apnoea [11, 37].

References

1. Davis L, Britten JJ, Morgan M. Cholinesterase Its significance in anaesthetic practice. *Anaesthesia* 1997;52:244-260. DOI: <https://doi.org/10.1111/j.1365-2044.1997.084-az0080.x>
2. Soliday FK, Conley YP, Henker R. Pseudocholinesterase deficiency: a comprehensive review of genetic, acquired, and drug influences. *AANA J* 2010;78 313-320.
3. Lehmann H, Liddell J. Human cholinesterase (pseudocholinesterase): genetic variants and their recognition. *Br J Anaesth* 1969;41:235-244. DOI: 10.1093/bja/41.3.235
4. Shah P, Jacobs D. Plasma cholinesterase deficiency in Turkish patients. *Anaesthesia* 2016;71:982-982. DOI: <https://doi.org/10.1111/anae.13559>
5. Manoharan I, Wieseler S, Layer PG et al. Naturally occurring mutation Leu307Pro of human butyrylcholinesterase in the Vysya community of India. *Pharmacogenet Genomics* 2006;16:461-468. DOI: 10.1097/01.fpc.0000197464.37211.77
6. Gutsche BB, Scott EM, Wright RC. Hereditary deficiency of pseudocholinesterase in Eskimos. *Nature* 1967; 215:322-323. DOI: 10.1038/215322b0
7. Kanariaris P, Fassoulaki A, Liarmakopoulou K et al. Serum cholinesterase levels in patients with cancer. *Anesth Analg* 1979;58:82-84.
8. Phillips BJ, Hunter JM. Use of mivacurium chloride by constant infusion in the anephric patient. *Br J Anaesth* 1992; 68:492-498. DOI: 10.1093/bja/68.5.492
9. Viby-Mogensen J, Hanel HK, Hansen E et al. Serum cholinesterase activity in burned patients I: biochemical findings. *Acta Anaesthesiol Scand* 1975;19:159-168. DOI: <https://doi.org/10.1111/j.1399-6576.1975.tb05236.x>
10. Wang Richard IH, Ross Charles A. Prolonged apnea following succinylcholine in cancer patients receiving AB-132. *Anesthesiology* 1963;24:363-367. DOI: 10.1097/00000542-196305000-00018
11. Whittaker M. Plasma cholinesterase variants and the anaesthetist. *Anaesthesia* 1980; 35:174-197. DOI: <https://doi.org/10.1111/j.1365-2044.1980.tb03800.x>
12. Andersson ML, Møller AM, Wildgaard K. Butyrylcholinesterase deficiency and its clinical importance in anaesthesia: a systematic review. *Anaesthesia* 2019;74:518-528. DOI: <https://doi.org/10.1111/anae.14545>
13. Kalow W, Staron N. On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers. *Can J Biochem Physiol* 1957;35:1305-1320.
14. Kalow W, Genest K. A method for the detection of atypical forms of human serum cholinesterase; determination of dibucaine numbers. *Can J Biochem Physiol* 1957;35:339-346. DOI: 10.1139/y57-041
15. Lovely MJ, Patteson SK, Beuerlein FJ et al. Perioperative blood transfusion may conceal atypical pseudocholinesterase. *Anesth Analg* 1990;70:326-327.
16. Gill RS, O'Connell N, Scott RPF. Reversal of prolonged suxamethonium apnoea with fresh frozen plasma in a 6-week-old infant. *Anaesthesia* 1991; 46: 1036-1038. DOI: <https://doi.org/10.1111/j.1365-2044.1991.tb09917.x>
17. Scholler KL, Goedde HW, Benkmann HG. The use of serum cholinesterase in succinylcholine apnoea. *Can Anaesth Soc J* 1977; 24: 396-400. DOI: 10.1007/bf03005113
18. Benzer A, Luz G, Oswald E et al. Succinylcholine-induced prolonged apnea in a 3-week-old newborn: treatment with human plasma cholinesterase. *Anesth Analg* 1992; 74: 137-138. DOI: 10.1213/00000539-199201000-00022
19. Eriksson LI. Evidence-based practice and neuromuscular monitoring: it's time for routine quantitative assessment. *Anesthesiology* 2003;98:1037-1039. DOI: 10.1097/00000542-200305000-00002
20. Viby-Mogensen J, Claudius C. Evidence-Based Management of Neuromuscular Block. *Anesth Analg* 2010;111: 1-2. DOI: 10.1213/ANE.0b013e3181e1d94c
21. Thomsen JL, Nielsen CV, Palmqvist DF et al. Premature awakening and underuse of neuromuscular monitoring in a registry of patients with butyrylcholinesterase deficiency†#. *BJA: Br J Anaesth* 2015;115:i89-i94. DOI: 10.1093/bja/aev103
22. Naguib M, Kopman AF, Lien CA et al. A survey of current management of neuromuscular block in the United States and Europe. *Anesth Analg* 2010;111:110-119. DOI: 10.1213/ANE.0b013e3181c07428
23. Thomsen JL, Nielsen CV, Eskildsen KZ et al. Awareness during emergence from anaesthesia: significance of neuromuscular monitoring in patients with butyrylcholinesterase deficiency. *Br J Anaesth* 2015;115 Suppl 1:i78-i88. DOI: 10.1093/bja/aev096

Date last modified: February 2025

This recommendation was prepared by:

Authors

Dr. med. Julia Schulze-Berge; Priv.-Doz. Dr. med. Tobias Hüppe D.E.S.A. E.D.I.C.,
Dept. of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University
Hospital Homburg, Germany

Reviewers

Prof. Dr. med. Thomas Wiesmann, Dept. of Anaesthesiology, Intensive Care Medicine
and Pain Therapy. Diak Klinikum Landkreis Schwäbisch Hall, Germany

Prof. Dr. med. Wolfram Henn, Institute for Human Genetics, University
Hospital Homburg/Saar, Germany

Disclosure The authors have no financial or other competing interest to disclose. This
recommendation was unfunded.

Disclosure The reviewers have no financial or other competing interest to disclose.

Herausgeber



DGAI

Deutsche Gesellschaft
für Anästhesiologie und
Intensivmedizin e. V.
Präsident: Prof. Dr. G. Marx,
Aachen



BDA

Berufsverband Deutscher
Anästhesistinnen und
Anästhesisten e. V.
Präsidentin: Prof. Dr.
G. Beck, Mannheim

Schriftleitung

Präsident/in der Herausgeberverbände

Gesamtschriftleiter/Editor-in-Chief:

Prof. Dr. Dr. Kai Zacharowski,
ML FRCA FESAIC, Frankfurt

Stellvertretender Gesamtschriftleiter/

Deputy Editor:

Prof. Dr. T. Volk, Homburg/Saar

CME-Schriftleiter/CME-Editor:

Prof. Dr. W. Zink, Ludwigshafen

Redaktionskomitee/Editorial Board

Priv.-Doz. Dr. E. Adam, Frankfurt

Prof. Dr. M. Adamzik, Bochum

Dr. J. Aulenkamp, Essen

Prof. Dr. G. Beck, Mannheim

Prof. Dr. T. Brenner, Essen

Prof. Dr. A. Brinkmann, Heidenheim

Prof. Dr. M. Coburn, Bonn

Prof. Dr. S.M. Coldewey, Zürich

Prof. Dr. V. von Dossow, Bad Oeynhausen

Prof. Dr. B. Ellger, Dortmund

Prof. Dr. K. Engelhard, Mainz

Prof. Dr. M. Fischer, Göttingen

Prof. Dr. D. Fries, Innsbruck

Prof. Dr. J.-T. Gräsner, Kiel

Prof. Dr. K. Hahnenkamp, Greifswald

Prof. Dr. A.R. Heller, Augsburg

Prof. Dr. B. Jungwirth, Ulm

Prof. Dr. T. Loop, Freiburg

Prof. Dr. K. Meissner, Göttingen

Prof. Dr. W. Meißner, Jena

Prof. Dr. P. Meybohm, Würzburg

Prof. Dr. T. Müller-Wolff, Ludwigsburg

Prof. Dr. H. Mutlak, Offenbach

Prof. Dr. C. Nau, Lübeck

Priv.-Doz. Dr. V. Neef, Frankfurt

Prof. Dr. B. O'Brien, Berlin

Dr. B. Oehler, Heidelberg

Prof. Dr. S.G. Sakka, Koblenz

Prof. Dr. M. Sander, Gießen

Prof. Dr. B. Saugel, Hamburg

Prof. Dr. S. Schäfer, Oldenburg

Priv.-Doz. Dr. H. Schöchl, Salzburg

Prof. Dr. A. Steinbicker, Köln

Dr. M.T. Völker, Leipzig

Prof. Dr. N.-M. Wagner, Würzburg

Prof. Dr. F. Wappler, Köln

Prof. Dr. M. Weigand, Heidelberg

Redaktion/Editorial Staff

Korrespondenzadresse:

Neuwieder Straße 9 | 90411 Nürnberg |

Deutschland | Tel.: 0911 9337812

E-Mail: redaktion@ai-online.info

Verlag & Druckerei

Aktiv Druck & Verlag GmbH

An der Lohwiese 36 |

97500 Ebelsbach | Deutschland

www.aktiv-druck.de



Geschäftsführung

Wolfgang Schröder | Jan Schröder

Tel.: 09522 9435-0 | Fax: 09522 9435-67

E-Mail: info@aktiv-druck.de

Anzeigen | Vertrieb

Pia Müller | Tel.: 09522 9435-70

E-Mail: anzeigen@aktiv-druck.de

Verlagsrepräsentanz

Jürgen Distler

Neuwieder Straße 9 | 90411 Nürnberg

Tel.: 0171 9432534

E-Mail: jdistler@bda-ev.de

Herstellung | Gestaltung

Pia Müller | Robert Kux | Stefanie Triebert

Tel.: 09522 9435-70

E-Mail: ai@aktiv-druck.de

Titelbild

Gestaltung: Roland Mehl

3D Arts GmbH

Landgrabenstraße 121 | 90459 Nürnberg

E-Mail: rmehl@3darts.de

www.3darts.de

Erscheinungsweise 2025

Der 66. Jahrgang erscheint jeweils zum
Monatsanfang, Heft 7/8 als Doppelausgabe.

Bezugspreise (inkl. Versandkosten):

• Einzelhefte 30,- €

• Jahresabonnement:

Europa (ohne Schweiz) 258,- €

(inkl. 7 % MwSt.)

Schweiz 266,- €

Rest der Welt 241,- €

Mitarbeiter aus Pflege, Labor, Studenten

und Auszubildende (bei Vorlage eines
entsprechenden Nachweises)

Europa (ohne Schweiz) 94,- €

(inkl. 7 % MwSt.)

Schweiz 90,- €

Rest der Welt 94,- €

**Für Mitglieder der DGAI und/oder
des BDA ist der Bezug der Zeitschrift
im Mitgliedsbeitrag enthalten.**

Allgemeine Geschäfts- und Lieferbedingungen

Die allgemeinen Geschäfts- und Lieferbedingungen entnehmen Sie bitte dem Impressum auf www.ai-online.info

Indexed in **CINAHL; Current Contents®/ Clinical Medicine, EBSCO; EMBASE/ Excerpta Medica; Medical Documentation Service; Research Alert; Sci Search; Scopus; SUBIS Current Awareness in Biomedicine; VINITI; Russian Academy of Science.**

Nachdruck | Urheberrecht

Die veröffentlichten Beiträge sind urheberrechtlich geschützt. Jegliche Art von Vervielfältigungen – sei es auf mechanischem, digitalem oder sonst möglichem Wege – bleibt vorbehalten. Die Aktiv Druck & Verlags GmbH ist allein autorisiert, Rechte zu vergeben und Sonderdrucke für gewerbliche Zwecke, gleich in welcher Sprache, herzustellen. Anfragen hierzu sind nur an den Verlag zu richten. Jede im Bereich eines gewerblichen Unternehmens zulässig hergestellte oder benutzte Kopie dient gewerblichen Zwecken gem. § 54 (2) UrhG. Die Wiedergabe von Gebrauchsnamen, Handelsnamen, Warenbezeichnungen usw. in dieser Zeitschrift berechtigt auch ohne besondere Kennzeichnung nicht zu der Annahme, dass solche Namen im Sinne der Warenzeichen- und Markenschutz-Gesetzgebung als frei zu betrachten wären und daher von jedermann benutzt werden dürften.

Wichtiger Hinweis

Für Angaben über Dosierungsanweisungen und Applikationsformen kann vom Verlag und den Herausgebern keine Gewähr übernommen werden. Derartige Angaben müssen vom jeweiligen Anwender im Einzelfall anhand anderer Literaturstellen auf ihre Richtigkeit überprüft werden. Gleiches gilt für berufs- und verbandspolitische Stellungnahmen und Empfehlungen.

Die Beiträge aus der A&I
finden Sie online unter:
www.ai-online.info

CONTACT US

Please do not hesitate to contact us. We will be glad to answer and provide further information to you at any time.

.....
Name

.....
First Name

.....
Department / Hospital

.....
Place

.....
Telephone

.....
E-Mail

.....
Date / Signature

Please contact me for further information

☐

I would like to participate in the project

☐

ADDRESS

German Society of Anaesthesiology and
Intensive Care Medicine
Neuwieder Straße 9 | 90411 Nuremberg | Germany
Tel.: +49-911-933780
Email: info@orphananesthesia.eu